Qualitative and Functional Investigation of Lipids in Patients With SARS-CoV2 Infection - In Search of Atherogenic Sequelae

Inclusion Criteria: Participants with a history of asymptomatic/mildly symptomatic SARS-CoV2 infection: * Age ≥18 years * Participant who has provided consent * Participant affiliated to National health insurance * Participant with asymptomatic or minimally symptomatic SARS CoV2 infection who did not require hospitalization at least 6 months prior to study inclusion. * SARS CoV2 infection proven by positive PCR or antigenic test at the time of signs of infection or positive SARS-CoV2 infection-specific serology at the time of infection (IgG+). Participants with a history of symptomatic SARS-CoV2 infection hospitalized at the Dijon University Hospital excluding the intensive care unit: * Age ≥18 years * Participant having provided consent * Participant affiliated to National health insurance * Participant having presented a symptomatic SARS CoV2 infection requiring admission to a regular hospital unit at least 6 months prior to inclusion in the study. * SARS CoV2 infection proven by a positive PCR or antigenic test at the time of signs of infection or a positive SARS-CoV2 specific serology at the time of infection (IgG+). Participants with a history of symptomatic SARS-CoV2 infection hospitalized at Dijon University Hospital in the ICU: * Age ≥18 years * Participant who has provided consent * Participant affiliated to National health insurance * Participant with symptomatic SARS CoV2 infection requiring admission to an intensive care unit at least 6 months prior to study inclusion. * SARS CoV2 infection proven by a positive PCR or antigenic test at the time of signs of infection or a positive SARS-CoV2 specific serology at the time of infection (IgG+). Participants with no history of SARS-CoV2 infection: * Age≥18 years * Participant who has provided consent * Participant affiliated to National health insurance * Participant with no evidence of SARS CoV2 infection and negative SARS-CoV2 serology. * For vaccinated participants: negative specific serology for SARS-CoV2 infection Exclusion Criteria: For all participants: * SARS Cov2 vaccination within one month prior to inclusion. * Previous SARS Cov1 infection documented * Previous study participant * Participant under legal protection (guardianship) * Participant subject to a legal protection measure * A protected adult * Pregnant, parturient or breastfeeding women * Treatment with corticosteroids in the last year * Treatment with lipid-lowering drugs * Known genetic mutation modifying HDL cholesterol * Progressive neoplasia * Chronic alcoholism * Primary biliary cirrhosis * Hyperthyroidism * Unstable hypothyroidism * History of cardiac or cardiovascular side effects following SARS-CoV2 vaccination (thrombosis, myocarditis etc) For participants with a history of asymptomatic/mildly symptomatic SARS-CoV2 infection: \- Hospitalization with a prior SARS-CoV2 infection in a conventional or intensive care unit For participants with a history of symptomatic SARS-CoV2 infection hospitalized outside the ICU: \- Previous ICU hospitalization for SARS-CoV2 infection For participants with no history of SARS-CoV2 infection: * Previous positive SARS-CoV2 PCR * Negative SARS-CoV2 PCR and presence of clinical symptoms suggestive of SARS-CoV2 infection * Previous positive serology for SARS-CoV2 infection Secondary exclusion criteria : For healthy volunteers with no history of SARS-CoV2 infection: Positive specific serology for SARS-CoV2 infection at the screening visit.